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Abstract
The role of Tau phosphorylation in neurofibrillary degeneration linked to Alzheimer’s disease remains to be established.
While transgenic mice based on FTDP-17 Tau mutations recapitulate hallmarks of neurofibrillary degeneration, cell models
could be helpful for exploratory studies on molecular mechanisms underlying Tau pathology. Here, ‘‘human neuronal cell
lines’’ overexpressing Wild Type or mutated Tau were established. Two-dimensional electrophoresis highlights that mutated
Tau displayed a specific phosphorylation pattern, which occurs in parallel to the formation of Tau clusters as visualized by
electron microscopy. In fact, this pattern is also displayed before Tau pathology onset in a well established mouse model
relevant to Tau aggregation in Alzheimer’s disease. This study suggests first that pathological Tau mutations may change
the distribution of phosphate groups. Secondly, it is possible that this molecular event could be one of the first Tau
modifications in the neurofibrillary degenerative process, as this phenomenon appears prior to Tau pathology in an in vivo
model and is linked to early steps of Tau nucleation in Tau mutants cell lines. Such cell lines consist in suitable and evolving
models to investigate additional factors involved in molecular pathways leading to whole Tau aggregation.
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Introduction
Tau (tubulin associated unit) is a microtubule-associated
protein. In the human brain, there are six Tau isoforms generated
by alternative splicing. They differ by the combination of 0, 1 or 2
amino-terminal inserts and 3- or 4-microtubule-binding repeats
(3R or 4R) encoded by exons 2,3 and 10 respectively. Tau
aggregation is one of the key features common to Tauopathies, a
group of neurodegenerative diseases including Alzheimer’s disease
(AD). Even though Tau is always found aggregated and
hyperphosphorylated in these pathologies, the precise role of
phosphorylation in Tau aggregation process is still debated. In the
same way, physiopathological significance of Tau aggregation
remains to be established. The discovery of Tau mutations
associated with Frontotemporal Dementia with Parkinsonism
linked to chromosome 17 (FTDP-17), has allowed for generating
several animal models and especially Tau transgenic mice that
display a Tau pathology characterized by abnormal phosphory-
lation and Tau aggregation [1–6]; and for review [7]. Beside these
in vivo models, many attempts have been done to generate cell
systems, which could recapitulate molecular features of Tau
pathology and then could be more appropriate to carry
exploratory studies on events involved in Tau aggregation and
its role in neuronal death. Two studies with specific Tau constructs
showed an abnormal Tau behaviour in cells. The first study based
on overexpression of N-terminal half truncated Tau bearing
DK280 mutation showed an increase in Tau aggregation [8]. The
second one showed that breaking specific motifs in microtubule
binding repeats [9] rapidly induce Tau aggregation and an
appearance of phosphoepitopes observed in AD-Tau pathology.
These models are interesting to give some insights into relationship
between Tau structure and its aggregation but it is not clear that
full-length Tau without these additional mutations follows the
same process of aggregation. Indeed, several strategies based on
either pharmacological treatments with okadaic acid and Hy-
droxy-nonenal [10] or overexpression of Tau bearing FTDP-17
mutations have been developed (for review [11]). Most of these
models with full-length Tau fail to identify early molecular
hallmarks of AD-Tau pathology. As almost of these studies have
been done in either non-human cells or in ‘‘non-neuronal’’ human
cells, the lack of Tau pathological features could be explained by
differences in molecular contents between neuronal and non-
neuronal cells. In the present work, using differentiated human
neuroblastoma cell lines, both wild type and mutated Tau proteins
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4843were analyzed by a proteomic approach to evaluate the potential
phosphorylation role in tau aggregation process.
Results
Characterisation of SH-SY5Y over-expressing 4RTau
In previous studies, we showed that, compared to 3R Tau,
constitutive over-expression of 4R Tau increased susceptibility of
SH-SY5Y neuroblastoma cells to cell death [12]. In order to avoid
4RTau toxicity and any interference with SY5Y differentiation,
stable cell lines were established using an inducible system. As
shown in Fig. 1A, endogenous Tau immunoreactivity was not
observed at low exposure. In non-induced 4RTau cell lines, a low
basal expression of exogenous Tau proteins due to a leak of the
inducible expression system was observed. After tetracycline
induction, a 4RTau expression was observed with a slight higher
Tau level in S305N Tau cells compared to WT and P301S cell
lines (Fig. 1B).
Analysis of Tau phosphorylation in differentiated SH-
SY5Y cells
Phosphorylation was monitored first by SDS-PAGE and
immunoblotting using anti-phospho-tau antibodies. Results
showed no significant alteration in tau phosphorylation among
the different cell lines at commonly studied AD deregulated
phosphoepitopes such as AT180, AT270, PHF-1 and 12E8 [13]
(data not shown).
To investigate overall Tau phosphorylation state, bidimensional
(2D) electrophoresis was performed, followed by an immunostain-
ing with Tau-exon10 antibody to reveal total exogenous 4RTau
(Fig. 2A). Analysis revealed about 10 species of Tau isovariants
that are displayed, for both WT and mutated 4RTau, on three
levels of apparent molecular weight (L1–L3). Interestingly, while
WT 4RTau isovariants are displayed over a wide range of
isoelectric point (pI) at mainly L1 molecular weight, isovariants for
P301S and S305N mutations are found proportionally at less acidic
pI and at higher molecular weight (L2 and L3). In fact, P301S and
S305N isovariants within the basic pI range displayed a molecular
weight shift. This shift, which is characterised by an increase in
isovariants number on high molecular weight levels (Fig. 2A: black
arrows, levels 2 (L2) an 3 (L3)) is indicative of a significant
difference in electrophoretic mobility between WT and mutated
4RTau consistent with phosphorylation [14]. To determine
whether such difference is linked to Tau phosphorylation status,
we performed in vitro Tau dephosphorylation by l-phosphatase
prior to 2D electrophoresis. Dephosphorylation efficiency was first
verified by SDS-PAGE followed by immunoblotting with
antibodies against phospho-Tau. As shown in Fig. 2C, a complete
dephosphorylation at AD2 epitope was observed after treatment
with l-phosphatase. Besides that, immunoblot with a total Tau
antibody revealed a higher electrophoretic mobility visualized as a
thin ‘‘down shift’’ of mutated 4RTau treated with l-phosphatase
(compared to untreated ones). This ‘‘down shift’’ is also observed
for dephosphorylated WT 4RTau, but to a lesser extent.
Analysis of dephosphorylated Tau by 2D-electrophoresis and
immunoblotting with Tau exon10 antibody showed that all
isovariants for both WT and mutated 4RTau are displaced into
the most basic pI range (Fig. 2B). More importantly, we observed
that the molecular weight ‘‘shift’’ of mutated 4RTau isovariants is
completely abolished after treatment by l-phosphatase. Altogether,
these data clearly support that, compared to WT 4RTau, mutated
4RTau likely display a difference in phosphorylation pattern which
is responsible for a substantial molecular weight ‘‘shift’’.
Overall Tau phosphorylation analysis in transgenic mice
To analyse relevance of the findings described above, 2D analysis
of Tau was performed in a recent characterized transgenic mouse
model relevant to Tau pathology in Alzheimer’s disease [1]. These
mice displayed a quite well defined neurofibrillary degeneration
time course, which is mainly characterized by Tau hyperpho-
sphorylation, abnormal Tau phosphorylation and appearance of
neuronal inclusions with ‘‘paired helical filaments’’ structures
between 6 to 10 months. These Tau abnormalities are associated
to spatial memory impairments. Analysis of overall Tau phosphor-
ylation by 2D analysis followed by immunoblots with antibodies
specifically directed against Total exogenous human Tau revealed
the presence of Tau isovariants in a pI range with high molecular
weight levels (L2 and L3) consistent with the pattern observed for
mutated TauinSH-SY5Ycell lines(Fig. 3).This analysisperformed
in brains of 3 weeks old mice suggest that this molecular event
appears very early in the degeneration process.
Tau aggregation analysis by electronic microscopy
As in transgenic mice the specific pattern of Tau phosphory-
lation precedes aggregation, human neuronal cell lines were
analyzed for Tau aggregation. Lysates from differentiated cells
were hence analysed by immunogold labeling electron microsco-
py. Results showed a Tau labelling, which is ‘‘clustered’’ on
opaque structures in mutant 4RTau cell lines (Fig. 4C and D:
Figure 1. Analysis of transgenes expression in 4RTau cell lines.
A) Lysates from Mock and 4RTau cells, treated or not (0) with
tetracycline for 24 to 48 hours were immunolabeled with TauCter
1902 (Total Tau), and b-actin as loading control. B) Quantification of Tau
expression levels in 4RTau cell lines: Ratios of densitometric values of
TauCter1902/b-actin immunoreactivities are presented. Ratios are
normalized to those obtained from WT 4RTau cells after 48 hours
tetracycline (arbitrary value=1).
doi:10.1371/journal.pone.0004843.g001
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lines since they are never observed neither in Mock or WT 4RTau
cell lines (Fig. 4A and B). Neverthelesss, as reported in previous
cellular models, these structures are still far different from the main
typical Tau aggregates found in Tauopathies since they are neither
straight nor paired helical filaments.
Discussion
Here, we reported a new model that allows an inducible over-
expression of either WT or mutated 4RTau bearing FTDP-17
mutations. This model may be appropriate to investigate
molecular events which could trigger Tau fibrillogenesis in a
‘‘neuronal like’’ cell context. Indeed, electron microscopy analysis
in our cell models showed no Tau aggregates similar to those
observed in transgenic mice models or pathological human brains.
It confirms results from a long list of previous cellular models,
which have never clearly shown the existence of such filaments.
However, as described in neuroglioma H4 cells [15], our cell lines
display some Tau clustering structures which may correspond to
very early starting points of Tau nucleation. These data likely
suggest that some additional factors could be involved in Tau
fibrillogenesis and then would be required to trigger the whole
tangle pathology.
In the present study, Tau phosphorylation was analysed by 2D
electrophoresis. FTDP-17 mutated 4RTau were found differen-
tially phosphorylated compared to WT 4RTau. Within the basic
pI range, the number of Tau isovariants with a L1 electrophoretic
mobility is higher in WT 4RTau than mutated Tau. More
importantly, 4RTau mutants isovariants showed a distinct 2D-
migration pattern characterised by a molecular weight shift
(towards L2 and L3), which is abolished after in vitro dephosphor-
ylation. This ‘‘shift’’ could be due to specific mode of Tau
phosphorylation so called ‘‘state I’’ described by Lindwall and col.
Figure 2. Analysis of Tau phosphorylation in 4RTau cell lines by 2D electrophoresis. A) Bi-dimensional analysis of WT and Mutated P301S
or S305N 4RTau. Differentiated cells treated with tetracycline for 48 hours were subjected to 2D analysis and immunoblotted with Tau Exon10
antibody (4RTau specific). Alignments of immunoblots were performed using unspecific products revealed by secondary antibody. Different
molecular weight (MW) levels (levels1–3: L1–L3) of Tau isovariants are represented by short dashed lines and pI indicators (obtained with an internal
IEF control) by long and short mixed dashed lines. B) Bi-dimensional analysis of WT and Mutated 4RTau after in vitro Tau dephosphorylation followed
by immunoblotting with Tau exon10 antibody. C) Immunoblot analysis of in vitro dephosphorylated WT and mutated (P301S and S305N) 4RTau.
Differentiated cells treated with tetracycline for 48 hours were subjected (+) or not (2), to an in vitro dephosphorylation by l-phosphatase and
immunoblotted by phosphorylation dependent antibody. Total amount of Tau proteins loaded is visualized with TauCter 1902 antibody (Total Tau)
and b-actin was used as loading control.
doi:10.1371/journal.pone.0004843.g002
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Histone H1 [17], that Tau proteins contain domains resistant to
SDS which remain under a folded state and migrate rapidly by
electrophoresis. Phosphorylation of a cluster of epitopes located in
these domains or their vicinity could lead to conformational
changes and hence allowing appearance of ‘‘stiffer’’ Tau forms,
which have a lower electrophoretic mobility. Moreover, it may be
hypothesized that these changes are not related to an increase in
Tau phosphorylation of commonly studied AD epitopes since our
analysis by classical SDS-PAGE revealed neither an increase nor a
decrease of phosphorylation at these epitopes in 4RTau mutants.
These data are coherent with previous studies, which similarly
report no significant change in Tau phosphorylation (for review
[11]). In fact, only rare FTDP-17 mutations such as R406W lead
to a decrease in Tau phosphorylation [18,19]. Finally, in order to
investigate the in vivo relevance of the molecular shift displayed in
mutated 4RTau cell lines, we performed the same overall
approach with a Tau transgenic mice model, which exhibits a
quite well defined Tau pathology associated to memory deficits
[1]. Interestingly, we observed the same Tau phosphorylation
pattern as in Tau mutants cell lines. More importantly, this
molecular shift is observed in 3-weeks old mice, before the main
features of Tau pathology, defined by the appearance of abnormal
and hyperphosphorylated Tau aggregates, that occurs in 6 to 10
months-old mice.
In summary, 2D approach reveals that P301S and S305N
4RTau mutants exist under a particular phosphorylation state.
Our data suggest that pathological Tau mutations may both
change distribution of phosphate groups and generate ‘‘clusters of
phosphorylation’’. This work could raise a common mechanism
for several FTDP-17 mutations, which could act through the
dysregulation of Tau phosphorylation status ultimately leading to
conformational changes. Finally, our data underline the possibility
that this molecular event could be one of the first Tau
modifications during the neurofibrillary degeneration cascade
since this phenomenon appears prior to Tau pathology in an in vivo
model and is linked to early step of Tau nucleation in Tau mutants
Figure 3. Analysis of overall Tau phosphorylation in THY-Tau
22 transgenic mice. Comparison of 2D analysis of human exogenous
Tau in 3-weeks old Thy-Tau22 trangenic mice and mutated P301S 4RTau
from SY5Y Cells. Alignments of immunoblots were performed using
unspecific products revealed by secondary antibody. Different molec-
ular weight (MW) levels (L1–L3) of Tau isovariants are represented by
short dashed lines and pI indicators (obtained with an internal IEF
control) by long and short mixed dashed lines. Exogenous Tau in mice
was probed by an anti-human Tau antibody and exogenous P301S
4RTau in SY5Y cells was visualized by Tau-Exon10 antibody.
doi:10.1371/journal.pone.0004843.g003
Figure 4. Analysis of Tau aggregation by electronic microscopy and Gold-immunolabeling. Lysates from differentiated Mock and 4RTau
cell lines, treated with tetracycline for 48 hours, were subjected to immunogold labelling with TauCter 1902 (Total Tau) antibody and revealed by
colloidal gold labelled secondary antibody. Images were obtained at high magnification: 20 0006. ‘‘Clustering’’ of Tau immunoreactivity is indicated
by black arrows.
doi:10.1371/journal.pone.0004843.g004
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investigate additional factors involved in molecular pathways
leading to whole Tau aggregation.
Materials and Methods
cDNA constructs
The Tau cDNA coding for the human 412 amino acids 4-
Repeat (4R) isoform was a kind gift from M. Goedert (Medical
Research Council Laboratory of Molecular Biology, Cambridge,
UK). A polymerase chain reaction (PCR)-based site-directed
mutagenesis (QuickChange, STRATAGENE, The Netherlands)
was used to generate two distinct constructs coding for the 4RTau
P301S or the 4RTau S305N mutants. Wild-type and mutated
cDNAs were sequenced and inserted in the tetracycline inducible
mammalian expression T-REX vector pcDNA4/TO  (INVI-
TROGEN, France).
Cell Culture and stable transfections
Generation of human SH-SY5Y cell line overexpressing
tetracycline repressor has been described elsewhere [20]. This
cell line was used for stable transfection of either pcDNA4/TO
empty vector or pcDNA4/TO containing Tau cDNAs (WT or
mutated). For differentiation, cells were maintained for 7 days in
DMEM/F12 medium supplemented with 2 mM L-glutamine,
50 U/mL penicillin/streptomycin, 7 mg/mL progesterone, 1%
Insulin/Transferrin/selenium (INVITROGEN) and 5 ng/ml b-
NGF (REPROTECH INC., TEBU, France) [21,22]. Medium
was replenished every 3 days. To induce transgenes expression,
cells are maintained in medium with 1 mg/ml tetracycline [20].
Electron microscopy and Gold-immunolabeling
Cells were harvested in MES buffer (0.1 M MES, 2 mM
MgCl2, 0.5 M EGTA, 1 mM NaCl, pH 6.5) with complete
protease inhibitors (ROCHE APPLIED SCIENCE, France) and
phosphatase inhibitor: 125 nM okadaic acid (SIGMA-ALDRICH,
France). Cells were lysed using a dounce homogenizer and then
collected on perlodion coated nickel-200 mesh grids. After 10 mn
blocking with 1% gelatine-PBS at room Temperature, grids were
incubated with TauCter 1902 antibody according to Table 1.
After washing, colloidal gold (18 nm) labelled-goat anti-rabbit
immunoglobulins were used. Finally, counterstaining was made in
4% uranyl acetate in H2O. Observations were done with a Zeiss
9025 electron microscope.
Western Blotting
Cells and mouse brain tissues were processed as previously
described [1,20]. Total proteins concentration was determined by
the BCA assay Kit (PIERCE, Perbio, France). Proteins were
mixed to LDS Sample Buffer containing a reducing agent
(INVITROGEN NP-009) and boiled at 100uC for 10 minutes,
as recommended by the manufacturer (INVITROGEN). For
SDS-PAGE, 10 mg of total proteins were loaded onto a 10%
acrylamide gel (Novex NuPAGEH INVITROGEN), blotted onto
nitrocellulose or polyvinylidene difluoride membranes (Hybond
and Hybond-Phosphate from AMERSHAM/GE HEALTH-
CARE, France). Membranes were blocked and incubated with
the appropriate antibody according to Table 1 and then incubated
with a Horseradish peroxidase-conjugated secondary antibody
(Goat anti-rabbit A4914 from SIGMA-ALDRICH and Horse
anti-mouse from Vector Laboratories). Finally, peroxidase activity
was revealed with the ECL detection kit and visualized with
Hyperfilm
TM ECL
TM (AMERSHAM/GE HEALTHCARE).
For two-Dimensional (2D) gel electrophoresis 100 mg of total
proteins were dissolved in 400 ml of 2D electrophoresis buffer (7 M
urea, 2 M thiourea, 4% (v/v) Triton X-100, 20 mM dithithreitol
and 0.6% (v/v) pharmalytes). Samples were loaded on immobi-
lized pH gradient ReadyStrip IPG strip 3–10 (BIORAD, France),
isoelectrofocused with the Protean IEF cell (BIORAD) by applying
a total of 75 kV/h, according to the manufacturer’s instructions
(For each experiment, samples are processed in the same run of
isoelectrofocalisation). The IPG strips were then equilibrated three
times (15 mn each) in a Laemmli Buffer (25 mM TrisHCl, 20 mM
DTT, 10% Glyce ´rol, 5% SDS, 0.05% Bromophenol Blue,
pH 6.8) and were layered onto a 10% Tris-Glycine Polyacryl-
amide Gel. SDS-PAGE was performed with a Protean II Xi Cell
(BIORAD) and blotted onto nitrocellulose or polyvinylidene
difluoride membranes with Criterion Blotter (BIORAD) as
recommended by the manufacturer. Membranes were then
incubated with either anti-E10tau antibody or anti human tau
antibody (Table 1).
Tau dephosphorylation In Vitro
Cells were harvested into an ice-cold NP-40 lysis buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40)
supplemented with protease inhibitors. Amount of total proteins
was determined using the BCA kit and 100 mg of total proteins,
with protease inhibitors to avoid any protein degradation, were
incubated at 37uC, for 80 minutes with l-protein phosphatase (EC
3.1.3.16) in reaction buffer (2 mM MgCl2, NEB reaction buffer
16) as recommended by the manufacturer (New England Biolabs,
Ozyme, France) [23]. Dephosphorylation was stopped on ice and
samples were immediately mixed to LDS Sample Buffer for SDS-
PAGE or dissolved in a 2D electrophoresis buffer for 2D analysis,
as described above.
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Table 1. Antibodies used in immunoblotting studies.
Antibody Species Specificity Dilution References
AD2 Mouse Tau; pSer396-pS404 1:20 000* [14]
M19G Rabbit Tau; human specific 1:20 000* [14]
TauCter 1902 Rabbit Total Tau 1:4 000* [24]
Tau-Exon10 (E10) Rabbit Total 4RTau 1:4 000* [25]
b-actin Mouse 1:50 000* Sigma-Aldrich
*Blocking: Tris-buffered saline, pH 8, 0.05% Tween 20+5% skim Milk.
doi:10.1371/journal.pone.0004843.t001
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